This prompted us to check whether any other critical modulators of the pathways related to CSC were altered by the combination treatment and found that the expression of SHH, which is up‐regulated in human breast tumours (Appendix S1: Figure S9A), is down‐regulated by the combination treatment (Appendix S1: Figure S9B). This evidence concerns the gene SHH and breast neoplasm.